

# CO.DON

## Green light for Spherox from the EMA

CO.DON is a leading manufacturer of autologous cell therapies for the treatment of cartilage defects. The company's main product, Spherox, is based on the core spheroid technology and can repair cartilage defects of the knee of up to  $10\text{cm}^2$  in a minimally invasive procedure. The Phase III clinical trial allowed CO.DON to obtain marketing authorisation from the European Medicine Agency (EMA) in July 2017, which opened access to all European markets. The company is preparing for the roll-out of Spherox and has already received a green light from the UK's National Institute for Health and Care Excellence (NICE).

### Autologous cell-based transplants for cartilage repair

CO.DON specialises in the regenerative treatment of articular cartilage defects. During a biopsy procedure healthy cartilage cells are taken from the patient's own cartilage as well as a blood sample. This is cultivated in a laboratory outside the body using CO.DON's innovative biological techniques to create cartilage, which is then transplanted back into the defect area. Following the EMA approval, Spherox is currently the only authorised advanced therapy medicinal product (ATMP).

## EMA's approval opens multiple European markets

Although CO.DON's products have been sold in Germany since 1997, the EMA authorisation was required for EU-wide distribution. The efficacy and safety of Spherox from a <a href="Phase III">Phase III</a> trial (n=102) are expected later this year. Meanwhile, three-year follow-up interim data from the <a href="Phase II trial">Phase II trial</a> (n=75) have shown significant improvements across two outcomes (patient-reported and imaging-based). Accumulated data from the trials supported the EMA's approval in July 2017.

### Valuation: EV of €183m

H117 revenues of €3.0m were flat y-o-y, while operating loss was €2.4m vs -€1.2m a year ago due to product roll-out and regulatory expenditure. Consensus estimates are for positive EBIT of €2.1m on sales of €20.7m in 2020. In October, CO.DON raised €15.5m gross and will invest in the expansion. Current estimated net cash is €20.1m, resulting in an EV of €183m; this appears undemanding given the opportunity to expand into multiple European markets. Especially encouraging is the recommendation of the method by the UK's NICE and a wholesale licence granted by the UK Medicines & Healthcare products Regulatory Agency (MHRA).


Consensus estimates						
Year end	Revenue (€m)	PBT (€m)	EPS (€)	DPS (€)	P/E (x)	Yield (%)
12/15	5.1	(2.9)	(0.18)	0.0	N/A	N/A
12/16	5.6	(3.7)	(0.23)	0.0	N/A	N/A
12/17e	6.2	(5.8)	(0.29)	0.0	N/A	N/A
12/18e	8.6	(5.8)	(0.29)	0.0	N/A	N/A

Source: Company data, Thomson Reuters

### Pharma & biotech

**14 November 2017** 





# Share details Code CNWK Listing Xetra Shares in issue 19.5m

### **Business description**

CO.DON is a biopharmaceutical company, focused on commercialising regenerative treatments for cartilage repair. Spherox, has received EMA marketing authorisation for knee cartilage repair and is on track to be launched in multiple European countries.

### Bull

- Established market base and successful distribution in Germany.
- Substantial expansion possible after the EU-wide marketing authorisation.
- Positive interim findings from clinical trials support efficacy and safety.

### Bear

- Visibility increased after EMA authorisation, which could invite competition (although clinical trials are lengthy).
- Although well financed now, any unexpected operational setbacks could lead to need for additional capital.
- Dependent on positive reimbursement decisions in other EU countries.

# **Analysts**Jonas Peciulis +44 (0) 20 3077 5728

healthcare@edisongroup.com

EDISON QUICKVIEWS ARE NORMALLY ONE OFF PUBLICATIONS WITH NO COMMITMENT TO WRITING ANY FOLLOW UP. QUICKVIEW NOTES USE CONSENSUS EARNINGS ESTIMATES.



Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world-renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisers and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting. Edison is authorised and regulated by the Financial Conduct Authority. Edison Investment Research (NZ) Limited (Edison NZ) is the New Zealand subsidiary of Edison. Edison NZ is registered on the New Zealand Financial Service Providers Register (FSP number 247505) and is registered to provide wholesale and/or generic financial adviser services only. Edison Investment Research Inc (Edison US) is the US subsidiary of Edison and is regulated by the Securities and Exchange Commission. Edison Investment Research Limited (Edison Aus) [46085869] is the Australian subsidiary of Edison and is not regulated by the Securities and Investment Commission. Edison Germany is a branch entity of Edison Investment Research Limited (Edison Commission).

### DISCLAIMER

Copyright 2017 Edison Investment Research Limited. All rights reserved. This report has been prepared and issued by Edison for publication globally. All information used in the publication of this report has been compiled from publicly available sources that are believed to be reliable, however we do not guarantee the accuracy or completeness of this report. Opinions contained in this report represent those of the research department of Edison at the time of publication. The securities described in the Investment Research may not be eligible for sale in all jurisdictions or to certain categories of investors. This research is issued in Australial by Edison Australian Corporations Act. The Investment Research may not be eligible for sale in all jurisdictions or to certain categories of investors. This research is sisted in Australial by Edison Australian Corporations Act. The Investment Research is distributed in the United States by Edison US to major US institutional investors only. Edison US is registered as an investment adviser with the Securities and Exchange Commission. Edison US relies upon the "publishers' exclusion" from the definition of investment adviser under Securities and Exchange Commission. Edison Ous Testes upon the "publishers' exclusion" from the definition of investment adviser under Securities and Edison does not offer or provide personalised advice. We publish information about companies in which we believe our readers may be interested and this information reflects our sincere opinions. The information that we provide or that is derived from our website is not intended to be, and should not be construed by any subscriber or prospective subscriber as Edison's solicitation to effect, or attempt to effect, any transaction in a security. The research in this document is intended for New Zealand resident professional financial advisers or brokers (for use in their roles as financial advisers or brokers) and habitual investors who are "wholesale clients" for the purpose of the Financial Advise